TCRT-PGEN Fundamental & Technical Discussion Board - The UK-based company thatís striving to overcome the limitations of T cell receptor innovation - TCRT-PGEN Fundamental & Technical Discussion Board - InvestorVillage


TCRT-PGEN Fundamental & Technical Discussion Board
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: TCRT-PGEN Fundamental & Technical Discussion Board   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  27763 of 28474  at  5/25/2022 3:26:42 PM  by

dnmun


 In response to msg 27762 by  Frank303
view thread

Re: The UK-based company thatís striving to overcome the limitations of T cell receptor innovation

i have followed these types of techniques that have been under development for almost 10 years now.
 
when you realize how really totally insightful was the work that dr Rosenberg did, to realize that he could find the right TCR by looking in the TIL for those individual T cells which were activated by being exposed to the tumor neoantigen in the grasp of the MHC on the antigen presenting cell, the dendritic cell..
 
i don't even know that much in this field, but for all of this work, using computer learning techniques, to have been pushed forward using such a primitive and machine learning dependent but still ineffective mechanism, reading what dr Rosenberg was doing while they struggled must have been kinda disappointing to the people who do this work.
 
but you gotta do something to write up a grant proposal and get some bureaucratic yahoo to approve funding for your own type of discovery technique. but none of this will ever be the way forward.
 
the use of the MilSeq machine to just read the RNA from the cells that are activated by exposure to that neoantigen peptide MHC held up on the dendritic cell makes the discovery of the TCR alpha and beta codding so simple.
 
and since we use the mouse beta chains for our work, we don't really even need to know the beta code from the MilSeq. and we know which cells are activated by reading the RNA that is produced to produce the activating signals, such as PD-1, that we used to measure using antibody titrations. everything has changed at lightning speed over the last few years. you could see it in those papers i posted.
 
this is what Drew did while he worked at the NCI surgery branch under dr Rosenberg. we are so far ahead of all these pretenders it just boggles the mind to realize that the shorts have been able to push the price down so low.
 
we should be trading over $10 right now. not in a year, but the news from this first patient will just be so spectacularly great that it will change everything overnight imo.
 
just news of the expansion of the transduced PBL of the initial dose should set off a run imo. 
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 26  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
27764 Re: The UK-based company thatís striving to overcome the limitations of T cell receptor innovation EconoTech 2 5/25/2022 6:53:29 PM
27767 Re: The UK-based company thatís striving to overcome the limitations of T cell receptor innovation dachmeister4u 20 5/25/2022 8:29:00 PM
27768 Re: The UK-based company thatís striving to overcome the limitations of T cell receptor innovation Bohsie 2 5/25/2022 9:03:14 PM


Financial Market Data provided by
.
Loading...